Published in Medical Letter on the CDC and FDA, October 15th, 2006
"Thiazolidinedione (TZD) therapy improves liver histology in NASH through a mechanism possibly related to its insulin-sensitizing or anti-inflammatory activity. This study was conducted to assess changes in serum levels of selected adipokines and proinflammatory cytokines and to relate these changes to the improved liver histology resulting from pioglitazone therapy for NASH," wrote G. Lutchman and colleagues, National Institute of Diabetes & Digestive & Kidney Diseases.
"Serum samples from 18 patients with NASH obtained at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.